Monday, January 6, 2014
Trovagene, a San Diego, Calif.-based developer of cell-free molecular diagnostics, and U.S. Oncology Research, a community-based research program in the U.S., have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients.
TauRx Therapeutics, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer’s disease, has expanded its international clinical trials by adding new research centers across the U.S. The addition of 35 clinical research centers means more patients suffering from mild or moderate Alzheimer’s, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx’s Alzheimer’s clinical trials.
Ampio Pharmaceuticals has announced that its subsidiary, biotechnology company Luoxis, has entered into research agreements with Western Galilee Medical Center and the University of Thessaly. These two oxidative stress research groups will utilize Luoxis’ proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis and physical exertion.
The Ethical Medicines Industry Group (EMIG) has welcomed the House of Commons Health Select Committee’s inquiry into the National Institute for Health and Clinical Excellence (NICE). This is an opportunity for the SME specialist biopharmaceutical sector to reflect on the workings of the medicines regulator, in particular its future role in supporting the new commissioning environment and how the value of innovative new medicines will be assessed.
Astellas Pharma and ClearPath Development have partnered to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas’ goal of building a global vaccine franchise and launched its first company, RSVC, in December 2013.
Starting this month, Sanofi will expand access to information and data from clinical trials sponsored by companies of the Sanofi group, in support of industry-wide efforts to promote a set of Principles for Responsible Sharing of Clinical Trial Data that the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) jointly released in July 2013 and put into effect Jan. 1.